IRIS
D'INCALCI, MAURIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.318
EU - Europa 2.187
AS - Asia 374
AF - Africa 21
OC - Oceania 5
SA - Sud America 5
Totale 9.910
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.304
FI - Finlandia 726
IE - Irlanda 501
FR - Francia 265
DE - Germania 214
CN - Cina 195
NL - Olanda 168
IN - India 146
GB - Regno Unito 96
SE - Svezia 64
BE - Belgio 51
IT - Italia 47
RU - Federazione Russa 20
NG - Nigeria 17
CA - Canada 7
JP - Giappone 6
PL - Polonia 6
SG - Singapore 6
CH - Svizzera 4
DK - Danimarca 4
ES - Italia 4
HK - Hong Kong 4
PA - Panama 4
RO - Romania 4
VN - Vietnam 4
AU - Australia 3
EG - Egitto 3
LU - Lussemburgo 3
MX - Messico 3
BG - Bulgaria 2
BR - Brasile 2
ID - Indonesia 2
IR - Iran 2
NZ - Nuova Zelanda 2
TR - Turchia 2
TW - Taiwan 2
AL - Albania 1
AT - Austria 1
BN - Brunei Darussalam 1
CL - Cile 1
CO - Colombia 1
DZ - Algeria 1
EE - Estonia 1
GE - Georgia 1
GR - Grecia 1
IL - Israele 1
MD - Moldavia 1
MN - Mongolia 1
MO - Macao, regione amministrativa speciale della Cina 1
MT - Malta 1
NO - Norvegia 1
PE - Perù 1
UA - Ucraina 1
Totale 9.910
Salva come PNG Salva come JPEG
Città #
Chandler 2.263
Helsinki 726
New York 530
Dublin 501
Lawrence 460
Princeton 460
Ashburn 423
Boardman 417
Paris 264
Shanghai 187
Amsterdam 159
Los Angeles 157
Pune 141
London 88
Brussels 51
Wilmington 37
Frankfurt am Main 32
Phoenix 30
Berlin 20
Moscow 18
Benin City 16
Falkenstein 15
San Mateo 14
Borås 12
Hanover 10
Milan 10
Ann Arbor 8
Leawood 6
Tokyo 6
Fairfield 5
Trieste 5
Warsaw 5
Boston 4
Chicago 4
Copenhagen 4
Padova 4
Stockholm 4
Woodbridge 4
Zurich 4
Cairo 3
Clifton 3
Desio 3
Hanoi 3
Mexico City 3
Rockville 3
Santa Clara 3
Seattle 3
Barnaul 2
Borgomasino 2
Buffalo 2
Champaign 2
Ferrara di Monte Baldo 2
Gunzenhausen 2
Hackensack 2
Hyderabad 2
Jakarta 2
Luxembourg 2
Munich 2
Pioltello 2
Rio Vista 2
Rome 2
Sofia 2
São Paulo 2
Taipei 2
Toronto 2
Treviglio 2
Veghel 2
Volendam 2
Washington 2
Ypsilanti 2
Ahmedabad 1
Alexandria 1
Algiers 1
Anaheim 1
Athens 1
Auckland 1
Bandar Seri Begawan 1
Birmingham 1
Bogotá 1
Bollebygd 1
Bucharest 1
Callao 1
Canberra 1
Central 1
Dalsjoefors 1
Deiva Marina 1
Genoa 1
Glasgow 1
Halethorpe 1
Hangzhou 1
Hull 1
Huế 1
Il-Madliena 1
Istanbul 1
Kingston 1
Kocaeli 1
Kolkata 1
Lagos 1
Manchester 1
Melbourne 1
Totale 7.204
Salva come PNG Salva come JPEG
Nome #
Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms 54
Breast and renal cancer-Derived endothelial colony forming cells share a common gene signature 53
A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma 51
Tumor Associated Macrophages: toward a better understanding of their cancer driver capability in Malignant Pleural Mesothelioma. 47
Pharmacokinetics of concomitant cisplatin and paclitaxel administration by hyperthermic intraperitoneal chemotherapy (HIPEC) to patients with peritoneal carcinomatosis 44
In silico rendering of cell cycle progression of erlotinib and gemcitabine treatment in pancreatic cancer cells 43
34. Trabectedin and indole-3-carbinol combination in heavily pretreated metastatic breast cancer: Results of a pilot clinical study 42
Mesothelioma. From research to clinical practice 40
Temozolomide drives mismatch repair deficiency and fosters neoantigen generation in tumor cells 40
E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models 40
How Medicines are Born. The Imperfect Science of Drugs 39
A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action 39
A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin 38
EPOC-experiences - conducting a multinational clinical trial on the pharmacology of doxorubicin in children with cancer 37
A biodistribution study of PEGylated PCL-based nanoparticles in C57BL/6 mice bearing B16/F10 melanoma 36
p21(WAF1)-derived peptides linked to an internalization peptide inhibit human cancer cell growth 36
Vinca alkaloids, taxanes and podophyllotoxins 36
N-Acetylcysteine Augments Surface Thiols and Differentially Modulates Cell Adhesion and Invasion in vitro and Metastatic Potential in vivo of B16F1 Melanoma 36
The combination of yondelis and cisplatin is synergistic against human tumor xenografts 35
Pharmacokinetic study of trabectedin administered as 24-hour infusion in elderly patients with advanced soft tissue sarcoma (STS) treated according to the TR1US ISG study 35
TRF2 inhibition triggers apoptosis and reduces tumourigenicity of human melanoma cells 35
A dose dense schedule improves antitumor activity of trabectedin in myxoid liposarcoma with type III FUS-CHOP chimera 35
COVID-19 epidemic strongly affected cancer research in Italy: a survey of the Italian Cancer Society (SIC) 34
A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma 34
In vitro Cytotoxic Effect of Trabectedin on JMML AND CMML Cell Populations 34
GEMCITABINE (G) AT FIXED DOSE RATE (FDR) INFUSION, COMBINED WITH CISPLATIN (C), IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC). A PHASE II STUDY WITH INCREMENTAL G DOSES 34
Drug development (including phase I trials) 34
Dalla biologia alle terapie mirate 34
HPLC-MS/MS method to measure trabectedin in tumors: preliminary PK study in a mesothelioma xenograft model 34
Evaluation of the pan-BET-bromodomain inhibitor OTX015 as a single agent and in combination with everolimus (RAD001) in triple-negative breast cancer 34
Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study 33
Quantitative measurement of pioglitazone in neoplastic and normal tissues by AP-MALDI mass spectrometry imaging 33
Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts 33
Mechanisms of responsiveness to and resistance against trabectedin in murine models of human myxoid liposarcoma 33
Activation of TGF-Beta Pathway Through Mir-181a and Psmad-2 Overexpression Drives Resistance To Neoadjuvant Chemotherapy in High Grade Serous Advanced Ovarian Cancer 33
Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study 33
DISTAMYCIN-A AND TALLIMUSTINE INHIBIT TBP BINDING AND BASAL IN-VITRO TRANSCRIPTION 33
Wiring miRNAs to pathways: a topological approach to integrate miRNA and mRNA expression profiles 33
HMGA1 is a new biomarker of liposarcoma progression 33
Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity 33
3-methyladenine-DNA-glycosylase and O-6-alkyl guanine-DNA-alkyltransferase activities and sensitivity to alkylating agents in human cancer cell lines 33
Karyotype instability and anchorage-independent growth in telomerase-immortalized fibroblasts from two centenarian individuals 33
Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences 33
RANDOMIZED, NON-COMPARATIVE, PHASE II TRIAL OF BEVACIZUMAB AND TRABECTEDIN WITH OR WITHOUT CARBOPLATIN IN PARTIALLY PLATINUM-SENSITIVE OVARIAN CANCER (ROC) WOMEN 33
SAFETY PROFILE AND TOLERABILITY OF 'TRABECTEDIN AND INDOLE-3-CARBINOL COMBINATION IN REFRACTORY ADVANCED BREAST CANCER. PRELIMINARY RESULTS OF PHASE 1 CLINICAL STUDY 33
Fsn0503h antibody-mediated blockade of cathepsin S as a potential therapeutic strategy for the treatment of solid tumors 32
The potential impact of marine compounds in the era of targeting therapies 32
Age dependence of doxorubicin pharmacokinetics in pediatric cancer patients; results of an FP7-funded clinical study 32
Binding of imatinib by alpha(1)-acid glycoprotein 32
Structure elucidation of taxol metabolites by liquid chromatography mass spectrometry and species differences in taxol metabolism - Reply 32
Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas 32
A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis assessment 32
Pharmacokinetic of the novel oral camptothecin gimatecan in women with pre-treated advanced breast cancer 31
Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin 31
O-6-METHYLGUANINE-DNA METHYLTRANSFERASE ACTIVITY AND INDUCTION OF NOVEL IMMUNOGENICITY IN MURINE TUMOR-CELLS TREATED WITH METHYLATING AGENTS 31
The Biological Connection Markup Language - a Data Format to Visualize, Annotate and Analyze Biological Pathways 31
Roots of clinical resistance to STI-571 cancer therapy 31
Copy number alterations in stage I epithelial ovarian cancer highlight three genomic patterns associated with prognosis 31
Modulation of gene transcription by natural products - A viable anticancer strategy 31
The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus 31
Induction of resistance to Aplidin (R) in a human ovarian cancer cell line related to MDR expression 31
Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels 31
microRNA-181a plays a critical role in ovarian cancer progression through the regulation of epithelial-mesenchymal transition 30
Pharmacokinetic of the novel oral camptothecin Gimatecan in patients with advanced or metastatic soft tissue sarcoma 30
Metabolic Approach to the Enhancement of Antitumor Effect of Chemotherapy: a Key Role of Acetyl-L-Carnitine 30
miRNA landscape analysis of stage I EOC, identifies miR-199a-5p associated to poor prognosis in grade 3 subgroup 30
p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel 30
Sequential administration of temozolomide and fotemustine: Depletion of O-6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours 30
Taxoids in combination with anthracyclines and other agents: Pharmacokinetic considerations 30
Characterization of a protein recognizing minor groove binders-damaged DNA 30
Lurbinectedin (PM01183): Antineoplastic Activity in Murine and Human Experimental Models 30
Plasma and intracellular pharmacokinetic (PK) study of prolonged infusion (PI) of gemcitabine (G) in combination with bolus cisplatin (C), in advanced nonsmall cell lung cancer.: Preliminary results 30
A Review of Trabectedin (ET-743): A Unique Mechanism of Action 30
DNA Damage Response and Immune Defense 30
3D Mass Spectrometry Imaging Reveals a Very Heterogeneous Drug Distribution in Tumors 30
MIRNA LANDSCAPE IN STAGE I EPITHELIAL OVARIAN CANCER DEFINES THE HISTOTYPE SPECIFICITIES 30
Phase I clinical and pharmacokinetic (PK) study of oral (PO) methoxy-morpholino doxorubicin (PNU 152243) on a single intermittent schedule 29
Genetic Instability Influences Drug Response in Cancer Cells 29
Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer 29
Cisplatin-induced peripheral neuropathy: Neuroprotection by erythropoietin without affecting tumour growth 29
PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models 29
Role of homologous recombination in trabectedin-induced DNA damage 29
L-asparagine-depletion: Another opinion - Response 29
A Specific miRNA Signature Correlates With Complete Pathological Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer 29
Trabectedin therapy for sarcomas 29
Idarubicinol myelotoxicity: a comparison of in vitro data with clinical outcome in patients treated with high-dose idarubicin 29
HIGH-DOSE MEDROXYPROGESTERONE ACETATE (MPA) IN ADVANCED EPITHELIAL OVARIAN-CANCER RESISTANT TO 1ST-LINE OR 2ND-LINE CHEMOTHERAPY 29
MIRNA181A-5P EXPRESSION AS A BIOMARKER OF TGFB PATHWAY ACTIVATION ASSOCIATED WITH ONCOLOGIC OUTCOME AND TUMOR DIFFUSION IN HIGH GRADE SEROUS EPITHELIAL OVARIAN CANCER 29
The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin 29
A Systems Biology Approach to Characterize the Regulatory Networks Leading to Trabectedin Resistance in an In Vitro Model of Myxoid Liposarcoma 29
Fsn0503h antibody-mediated blockade of cathepsin S as potential therapeutic strategy for the treatment of solid tumors 29
Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients 29
Activity and safety of trabectedin in patients with sarcomatoid / biphasic malignant pleural mesothelioma (MPM) 29
Striking activity of E-3810 combined with paclitaxel and 5FU in the triple negative breast cancer model MDA-MB-231 29
Selective effects of the anticancer drug Yondelis (ET-743) on cell-cycle promoters 28
Optimization of a Luciferase-Expressing Non-Invasive Intrapleural Model of Malignant Mesothelioma in Immunocompetent Mice 28
Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein 28
Readily prepared biodegradable nanoparticles to formulate poorly water soluble drugs improving their pharmacological properties: The example of trabectedin 28
A novel taxane active against an orthotopically growing human glioma xenograft 28
High dose idarubicin and melphalan after sequential high dose chemotherapy (S-HDC) for lymphomas: Preliminary results of a phase I-II study 28
Totale 3.302
Salva come PNG Salva come JPEG
Categoria #
all - tutte 79.945
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 79.945
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201 0 0 0 0 0 0 0 0 0 0 0 1
2020/202164 0 0 1 0 0 22 9 7 13 5 0 7
2021/2022244 2 4 0 7 1 0 0 7 19 5 67 132
2022/20236.451 1.028 151 587 747 428 614 5 689 1.147 573 412 70
2023/20243.171 333 309 938 283 106 679 113 195 39 176 0 0
Totale 9.931